Sterling Pharmaceutical Services LLC, located in Dupo, Illinois, has issued a significant recall of almost 750,000 eye-care products, raising concerns about the safety and sterility of these items. This sweeping recall, announced on 20 August, includes over half a million eye drop products distributed under various brand names, such as Walgreens.
:max_bytes(150000):strip_icc():format(jpeg)/eye-drops-070926-d26177bc6de8428cbf4ea64203865e82.jpg)
The recall has been classified as a Class II by the U.S. Food and Drug Administration (FDA), which indicates that while there is a remote chance of serious health consequences, the risk of temporary or reversible adverse effects is present. The FDA made this classification formal on 21 September, advising consumers to cease using the affected products and consult their healthcare providers.
Two of the brands implicated in this recall are Walgreens and AvKare. The recall covers a comprehensive range of products, primarily focusing on Walgreens’ lubricant eye drops. Specifically, the affected batch includes approximately 301,114 bottles of Walgreens Lubricant Eye Drops, each containing 0.5 fluid ounces, in addition to 199,600 twin-packs of the same eye drops distributed by Walgreens.
In addition to Walgreens products, the recall also involves various items from AvKare and Reliable-1 Laboratories. The affected AvKare products include about 12,864 bottles of Carboxymethylcellulose Sodium Ophthalmic Solution, along with 107,377 two-count twin-pack units. Reliable-1 Laboratories contributes to the recall with roughly 11,083 bottles of Sodium Chloride Hypertonicity Ophthalmic Solution and 47,616 bottles of their Lubricating Tears, both in 0.5 fluid ounces.
Further included in the recall are items such as 19,284 bottles of Cameron Pharmaceuticals’ Carboxymethylcellulose Sodium Lubricant Eye Drops and other related products from TRP The Relief Products and Major Pharmaceuticals. This extensive list signals a considerable issue regarding product sterility across multiple brands and manufacturers.
Customers who believe they possess any of the recalled eye drop products are urged to discontinue use immediately. It is advisable to consult with healthcare professionals regarding any concerns or symptoms that may arise from using these products.
The FDA has previously taken action in similar instances, including the recall of over 39,000 bottles of Clear Eyes Maximum Itchy Eye Relief and 2.5 million bottles of prescription eye drops from Lupin Pharmaceuticals due to contamination issues earlier in the year. These recurrent recalls underscore ongoing concerns regarding the regulation and safety of over-the-counter eye care products.
As more individuals become aware of the risks associated with the use of these eye drops, it is paramount for health agencies and manufacturers to ensure stringent quality control measures are in place to protect consumers. As of now, Sterling Pharmaceutical Services has not released a public statement addressing further measures or recall procedures, and consumers are left on high alert regarding their eyecare products.
Anyone who experiences adverse effects or has questions related to the recall is encouraged to reach out directly to healthcare providers for assistance, while also keeping an eye on updates from the FDA. The evolving nature of health product safety calls for increased diligence from both manufacturers and consumers alike.